Navigation Links
Freedom Meditech to Provide Live Demonstration of ClearPath DS-120 Eye Scan at the 13th Annual Diabetes Technology Meeting
Date:10/30/2013

SAN DIEGO, Oct. 30, 2013 /PRNewswire/ -- Freedom Meditech, Inc. has announced that the company has been invited to present a live demonstration of the ClearPath DS-120™ at the 13th Annual Diabetes Technology Meeting, the premier event in the United States for showcasing latest technological advances for people with diabetes. Cleared by the U.S. Food and Drug Administration (FDA) in January 2013, the ClearPath DS-120 is a first-in-class, non-invasive tool designed to quickly and accurately measure autofluorescence through a six second scan of the crystalline lens of the eye. A significant number of independent peer-reviewed studies have suggested that elevated lens autofluorescence may be an early indicator of the presence of diabetes.

"The Diabetes Technology Meeting provides an opportunity to educate diabetes professionals about the clinical value of non-invasive lens autofluorescence and the associated market size estimated at $4 billion worldwide," said Craig Misrach, CEO of Freedom Meditech. "ClearPath can facilitate the co-management of patients between physicians and eye care professionals, which in turn, can maximize earlier detection and monitoring of patients at risk of developing complications related to diabetes."

The meeting will feature more than 500 clinicians and scientists from 24 countries and will focus on applying science and technology to prevent and treat diabetes. The goal of the meeting is to facilitate the creation of new and cost-effective tools between diabetes thought leaders and developers.

"The most cutting-edge inventions in the global diabetes marketplace are featured at the Diabetes Technology Meeting and it's only appropriate that non-invasive lens autofluorescence be included," said David C. Klonoff, M.D., F.A.C.P., chair of the Diabetes Technology Meeting. "Technologies that enable the early detection of diabetes with a footprint capable of reaching a wider patient population are essential to disease intervention and reversing the direction of the Type 2 diabetes epidemic."

Freedom Meditech will conduct a live demonstration of the ClearPath at 2:10 p.m. on November 2, 2013 at the Diabetes Technology Meeting taking place at the Hyatt Regency San Francisco Airport in Burlingame, California.

About ClearPath DS-120™

The ClearPath DS-120™ Lens Fluorescence Biomicroscope is cleared by FDA as a tool for the measurement of autofluorescence by scanning the crystalline lens of the eye with a blue light. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products which accumulate as a result of the aging process and the presence of systemic disease.

The ClearPath scan is pain free, takes just six seconds and produces an immediate, quantitative result available to the patent and healthcare provider. Unlike some eye exams, the scan does not require dilation. The ClearPath is completely non-invasive and does not require a blood draw to produce a result. The device has a small footprint, sits on a table top, and employs an easy to use touch screen display that can be wirelessly linked to a practitioner's electronic medical record system.

About Freedom Meditech

Freedom Meditech, Inc. is a medical device company focused on the commercialization of novel ophthalmic technologies for the detection of disease and management of patient health. The company has received FDA clearance for its first product, ClearPath DS-120™, a non-invasive tool for the measurement of autofluorescence in the eye. I-SugarX is the company's second product currently in development as a non-invasive ophthalmic glucose monitor that measures glucose levels in the eye for people with diabetes. The company maintains corporate and engineering operations in San Diego, CA with supporting research and development activities throughout the state of Ohio. For more information, visit www.freedom-meditech.com or find us on TwitterFacebook and LinkedIn.


'/>"/>
SOURCE Freedom Meditech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
2. Freedom Innovations Wins the American Technology Award for Health & Medical Technologies
3. FreedomPACS, Radiology PACS and Cloud Image Storage Provider, Releases Results of County Hospital Case Study, Revealing Savings of 75 Percent
4. Updated HHS Mandate Continues Attack on Religious Freedom
5. AUL Files Seventh Brief Supporting First Amendment Freedom of Conscience
6. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
7. OralHygenix Announces Freedom Oral Care System (FOCS) for People with Physical and Mental Disabilities
8. Golden Meditech Holdings Limited Announces 2011/ 2012 Annual Results
9. Golden Meditech Holdings Limited Announces Updates on Medical Devices Subsidiary Latest Development
10. Golden Meditech Announces 2012 / 2013 Interim Results
11. Zynx Health Launches Unrivaled MEDITECH Integration for Evidence-based Care Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CAMBRIDGE , United Kingdom and  BOSTON ... text analytics provider Linguamatics today announced ... Dow Jones . The agreement allows pharmaceutical companies ... utilizing Linguamatics I2E text mining technology. ... used by 18 of the top 20 global ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With expansion and ... Georgia, in early March. , The seed processing plant opened in Marshallville in 2006, ... 2016. The new office allows opportunity for transition of Patten Seed operations to the ...
Breaking Medicine News(10 mins):